1

2

3

4

5
Michael R Myers, Alfred P Spada, Paul E Persons, Martin P Maguire: Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56.sup.lck tyrosine kinases. Aventis Pharmaceuticals Product, Irving Newman, Peter Butch, December 12, 2000: US06159978 (182 worldwide citation)

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to diso ...


6
Michael R Myers, Alfred P Spada, Paul E Persons, Martin P Maguire: Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases. Avantis Pharmaceuticals, Peter J Butch, Raymond S Parker III, February 25, 2003: US06524347 (181 worldwide citation)

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to diso ...


7
Alfred P Spada, Michael R Myers, Martin P Maguire, Paul E Persons: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, James A Nicholson, Martin F Savitzky, Raymond S Parker III, January 2, 1996: US05480883 (166 worldwide citation)

This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferatio ...


8
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons: Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, James A Nicholson, Martin F Savitzky, January 20, 1998: US05710158 (144 worldwide citation)

This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compou ...


9
Alfred P Spada, Martin P Maquire, Paul E Persons, Michael R Myers: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, James A Nicholsen, Martin F Savitzky, Raymond S Parker III, April 25, 1995: US05409930 (127 worldwide citation)

This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferatio ...


10
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons: Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, James A Nicholson, Martin F Savitzky, February 24, 1998: US05721237 (110 worldwide citation)

This invention relates to a method for the selective treatment of cell growth and differentiation characterized by activity of the human epidermal growth factor receptor type 2 (HER2). More specifically, this invention relates to the use of substituted or unsubstituted mono- or bi-cyclic aryl, heter ...